Works by Bergsagel, P.
Results: 74
Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-κB signaling.
- Published in:
- Nature Immunology, 2008, v. 9, n. 12, p. 1364, doi. 10.1038/ni.1678
- By:
- Publication type:
- Article
Exploring BCL2 regulation and upstream signaling transduction in venetoclax resistance in multiple myeloma: potential avenues for therapeutic intervention.
- Published in:
- Blood Cancer Journal, 2025, v. 14, n. 1, p. 1, doi. 10.1038/s41408-025-01215-x
- By:
- Publication type:
- Article
Correction: Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Mass Cytometry reveals unique phenotypic patterns associated with subclonal diversity and outcomes in multiple myeloma.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00851-5
- By:
- Publication type:
- Article
Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00820-y
- By:
- Publication type:
- Article
Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00794-x
- By:
- Publication type:
- Article
Mass Cytometry reveals unique phenotypic patterns associated with subclonal diversity and outcomes in multiple myeloma.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00851-5
- By:
- Publication type:
- Article
Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00820-y
- By:
- Publication type:
- Article
Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00794-x
- By:
- Publication type:
- Article
Distribution of clonal hematopoiesis of indeterminate potential (CHIP) is not associated with race in patients with plasma cell neoplasms.
- Published in:
- 2022
- By:
- Publication type:
- Letter
The CCND1 c.870G risk allele is enriched in individuals of African ancestry with plasma cell dyscrasias.
- Published in:
- 2020
- By:
- Publication type:
- Letter
Mate pair sequencing outperforms fluorescence in situ hybridization in the genomic characterization of multiple myeloma.
- Published in:
- Blood Cancer Journal, 2019, v. 9, n. 12, p. 1, doi. 10.1038/s41408-019-0255-z
- By:
- Publication type:
- Article
Polyclonal serum free light chain elevation is associated with increased risk of monoclonal gammopathies.
- Published in:
- Blood Cancer Journal, 2019, v. 9, n. 6, p. N.PAG, doi. 10.1038/s41408-019-0210-z
- By:
- Publication type:
- Article
Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy.
- Published in:
- Bone Marrow Transplantation, 2014, v. 49, n. 2, p. 201, doi. 10.1038/bmt.2013.175
- By:
- Publication type:
- Article
Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma.
- Published in:
- Cell Death & Disease, 2013, v. 4, n. 9, p. 1, doi. 10.1038/cddis.2013.306
- By:
- Publication type:
- Article
Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 6, p. 456, doi. 10.1016/j.clml.2023.03.002
- By:
- Publication type:
- Article
Advances in the pathogenesis and diagnosis of multiple myeloma.
- Published in:
- International Journal of Laboratory Hematology, 2015, v. 37, p. 108, doi. 10.1111/ijlh.12360
- By:
- Publication type:
- Article
Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Initial genome sequencing and analysis of multiple myeloma.
- Published in:
- Nature, 2011, v. 471, n. 7339, p. 467, doi. 10.1038/nature09837
- By:
- Publication type:
- Article
MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites.
- Published in:
- Nature, 2011, v. 470, n. 7332, p. 124, doi. 10.1038/nature09658
- By:
- Publication type:
- Article
Longitudinal single-cell analysis of a myeloma mouse model identifies subclonal molecular programs associated with progression.
- Published in:
- Nature Communications, 2021, v. 12, n. 1, p. 1, doi. 10.1038/s41467-021-26598-w
- By:
- Publication type:
- Article
Rational therapy targeting the initial genetic event in multiple myeloma: FGFR3 as a drug target in t(4;14) myeloma.
- Published in:
- European Journal of Haematology, 2003, v. 70, n. 4, p. 268, doi. 10.1034/j.1600-0609.2003.10910.x
- By:
- Publication type:
- Article
Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma.
- Published in:
- British Journal of Haematology, 2015, v. 169, n. 2, p. 219, doi. 10.1111/bjh.13296
- By:
- Publication type:
- Article
Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma.
- Published in:
- British Journal of Haematology, 2014, v. 167, n. 4, p. 563, doi. 10.1111/bjh.13004
- By:
- Publication type:
- Article
Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma.
- Published in:
- British Journal of Haematology, 2014, v. 165, n. 5, p. 1, doi. 10.1111/bjh.13004
- By:
- Publication type:
- Article
A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma.
- Published in:
- British Journal of Haematology, 2012, v. 156, n. 3, p. 326, doi. 10.1111/j.1365-2141.2011.08949.x
- By:
- Publication type:
- Article
Che-1-induced inhibition of mTOR pathway enables stress-induced autophagy.
- Published in:
- EMBO Journal, 2015, v. 34, n. 9, p. 1214, doi. 10.15252/embj.201489920
- By:
- Publication type:
- Article
V. Molecular classification and risk stratification of myeloma.
- Published in:
- Hematological Oncology, 2013, v. 31, p. 38, doi. 10.1002/hon.2065
- By:
- Publication type:
- Article
Type I-conventional dendritic cells support the progression of multiple myeloma in the bone marrow.
- Published in:
- Frontiers in Immunology, 2024, p. 1, doi. 10.3389/fimmu.2024.1444821
- By:
- Publication type:
- Article
Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma.
- Published in:
- Leukemia (08876924), 2014, v. 28, n. 8, p. 1725, doi. 10.1038/leu.2014.70
- By:
- Publication type:
- Article
Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276.
- Published in:
- Leukemia (08876924), 2013, v. 27, n. 12, p. 2357, doi. 10.1038/leu.2013.172
- By:
- Publication type:
- Article
Degree of focal immunoglobulin heavy chain locus deletion as a measure of B-cell tumor purity.
- Published in:
- Leukemia (08876924), 2013, v. 27, n. 10, p. 2067, doi. 10.1038/leu.2013.139
- By:
- Publication type:
- Article
Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM).
- Published in:
- 2010
- By:
- Publication type:
- journal article
Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma.
- Published in:
- 2010
- By:
- Publication type:
- journal article
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.
- Published in:
- 2009
- By:
- Publication type:
- journal article
Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.
- Published in:
- 2009
- By:
- Publication type:
- journal article
Reply to the research mission in myeloma by Richardson et al.
- Published in:
- 2009
- By:
- Publication type:
- Letter
Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma.
- Published in:
- 2008
- By:
- Publication type:
- Letter
Genetic aberrations and survival in plasma cell leukemia.
- Published in:
- 2008
- By:
- Publication type:
- journal article
Expression and mutation status of candidate kinases in multiple myeloma.
- Published in:
- 2008
- By:
- Publication type:
- Correction Notice
A kinder, gentler way: control of the proliferative tumor compartment, not cosmetic complete response, should be the goal of myeloma therapy.
- Published in:
- 2008
- By:
- Publication type:
- Editorial
Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature.
- Published in:
- 2008
- By:
- Publication type:
- Letter
Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature.
- Published in:
- 2008
- By:
- Publication type:
- Correction Notice
Diagnostic evaluation of t(4;14) in multiple myeloma and evidence for clonal evolution.
- Published in:
- 2007
- By:
- Publication type:
- Letter
Expression and mutation status of candidate kinases in multiple myeloma.
- Published in:
- 2007
- By:
- Publication type:
- Letter
A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy.
- Published in:
- Leukemia (08876924), 2007, v. 21, n. 3, p. 529, doi. 10.1038/sj.leu.2404516
- By:
- Publication type:
- Article
Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma.
- Published in:
- Leukemia (08876924), 2006, v. 20, n. 11, p. 2034, doi. 10.1038/sj.leu.2404403
- By:
- Publication type:
- Article
Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations.
- Published in:
- Leukemia (08876924), 2006, v. 20, n. 5, p. 807, doi. 10.1038/sj.leu.2404172
- By:
- Publication type:
- Article
Maintained rules of development in a mouse B-cell tumor.
- Published in:
- 2005
- By:
- Publication type:
- Letter